PTC Therapeutics price target raised to $46 from $42 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on PTC Therapeutics (PTCT) to $46 from $42 and keeps an Equal Weight rating on the shares. The company’s Sephience received FDA approval in phenylketonuria, with a largely comparable label to BioMarin’s (BMRN) Kuvan and a slightly different safety profile, the analyst tells investors in a research note. However, Sephience’s pricing of $490,000 is at a “huge premium” versus Kuvan, the firm points out.